Published in Antimicrob Agents Chemother on March 01, 1987
Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med (2011) 2.18
Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis (1991) 1.33
The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin. Br J Ophthalmol (2002) 0.90
In vitro toxicological evaluation of ISIS 1082, a phosphorothioate oligonucleotide inhibitor of herpes simplex virus. Antimicrob Agents Chemother (1992) 0.82
Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. Antimicrob Agents Chemother (1993) 0.77
Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection. BMC Dermatol (2009) 0.75
Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother (1987) 0.75
Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med (1981) 5.44
Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.02
Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A (1980) 3.32
Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet (1982) 3.23
Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med (1981) 3.19
Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med (1983) 2.91
Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A (1980) 2.72
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Intravenous acyclovir treatment for primary genital herpes. Lancet (1982) 2.45
Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med (1982) 2.37
Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet (1982) 2.28
Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med (1984) 2.26
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA (1984) 2.20
Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob Agents Chemother (1980) 2.17
Prophylactic oral acyclovir in recurrent genital herpes. Lancet (1984) 1.99
Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA (1984) 1.94
Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother (1982) 1.80
Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy. J Antimicrob Chemother (1983) 1.68
Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med (1982) 1.67
Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med (1983) 1.59
Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet (1981) 1.58
Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis (1982) 1.56
Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. Am J Med (1982) 1.42
Infectious complications in heart-lung transplant recipients. Am J Med (1985) 1.40
Preclinical toxicology profile of acyclovir: an overview. Am J Med (1982) 1.37
Reactivation of herpes simplex virus after decompression of the trigeminal nerve root. J Infect Dis (1978) 1.32
Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med (1984) 1.31
Acyclovir and suppression of frequently recurring herpetic whitlow. Ann Intern Med (1985) 1.29
Herpesvirus infection in burned patients. N Engl J Med (1970) 1.26
Topical acyclovir in the treatment of initial genital herpes. Br J Vener Dis (1983) 1.26
Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis (1983) 1.23
Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet (1981) 1.22
Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med (1983) 1.18
Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med (1982) 1.16
Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother (1983) 1.15
Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro. Antimicrob Agents Chemother (1980) 1.14
Virus resistance in clinical practice. J Antimicrob Chemother (1983) 1.13
Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med (1986) 1.13
In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. J Infect Dis (1983) 1.12
Oral acyclovir to suppress recurring herpes simplex virus infections in immunodeficient patients. Ann Intern Med (1984) 1.11
Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med (1986) 1.09
Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Infect Dis (1984) 1.09
Effect of acyclovir on the proliferation of human fibroblasts and peripheral blood mononuclear cells. Antimicrob Agents Chemother (1980) 1.01
Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study. Acta Derm Venereol (1985) 1.00
Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation. J Antimicrob Chemother (1983) 0.97
Post-herpetic erythema multiforme prevented with prophylactic oral acyclovir. Ann Intern Med (1985) 0.96
Recurrent oral erythema multiforme. Clinical experience with 11 patients. JAMA (1983) 0.96
Comparative in vitro imunotoxicology of acyclovir and other antiviral agents. Infect Immun (1980) 0.95
Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA (1985) 0.91
Acyclovir in first attacks of genital herpes and prevention of recurrences. Genitourin Med (1986) 0.91
Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation. J Antimicrob Chemother (1985) 0.88
Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. J Antimicrob Chemother (1983) 0.86
RECURRENT ECZEMA HERPETICUM. WIDESPREAD CUTANEOUS HERPES SIMPLEX IN ATOPIC PATIENT WITHOUT ACTIVE ATOPIC DERMATITIS. Arch Dermatol (1964) 0.86
Reactivation of type 2 herpes simplex virus by thoracolumbar neurosurgery. Ann Intern Med (1984) 0.82
Isolation of herpes simplex virus type I in recurrent (Mollaret) meningitis. Ann Neurol (1982) 0.82
Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann Intern Med (1985) 0.82
Prophylaxis: a strategy to minimise antiviral resistance. Lancet (1984) 0.79
Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes. Antiviral Res (1986) 0.77
Historical findings in subjects from a high socioeconomic group who have genital infections with herpes simplex virus. Sex Transm Dis (1999) 0.77
Recurrent erythema multiforme and Herpes genitalis (type 2). JAMA (1975) 0.77
Pathways to new drugs. Scand J Infect Dis Suppl (1985) 0.76
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med (1983) 7.89
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
A role for CD95 ligand in preventing graft rejection. Nature (1995) 6.07
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Plasma viremia in human immunodeficiency virus infection. N Engl J Med (1989) 5.73
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Chronic fatigue in adolescents. Pediatrics (1991) 5.24
Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS (1988) 4.85
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 4.54
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med (2000) 4.39
Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection. J Clin Microbiol (1981) 4.10
Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med (1995) 4.03
Risk factors for the sexual transmission of genital herpes. Ann Intern Med (1992) 3.89
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med (1994) 3.83
The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA (1988) 3.73
The acquisition of herpes simplex virus during pregnancy. N Engl J Med (1997) 3.73
Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ (1994) 3.71
A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med (1982) 3.66
Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med (1992) 3.56
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest (1997) 3.52
Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med (1993) 3.51
Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol (1999) 3.48
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med (1996) 3.35
Sexual transmission of hepatitis A in homosexual men: incidence and mechanism. N Engl J Med (1980) 3.33
Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med (1981) 3.32
Infections with herpes simplex viruses (1). N Engl J Med (1986) 3.26
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med (1991) 3.19
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med (1983) 3.12
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA (1998) 3.03
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest (1998) 2.85
Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med (1995) 2.83
Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. J Infect Dis (2001) 2.79
Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med (1987) 2.74
Sexually transmitted diseases in victims of rape. N Engl J Med (1990) 2.74
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis (1998) 2.72
Predictors of asthma and persistent wheeze in a national sample of children in the United States. Association with social class, perinatal events, and race. Am Rev Respir Dis (1990) 2.71
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med (1984) 2.71
Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis (1985) 2.64
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med (1999) 2.62
Monoclonal antibodies to herpes simplex viruses: use in antigenic typing and rapid diagnosis. J Infect Dis (1983) 2.60
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Chronic fatigue. A prospective clinical and virologic study. JAMA (1990) 2.54
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet (1994) 2.53
Typing of clinical herpes simplex virus isolates with mouse monoclonal antibodies to herpes simplex virus types 1 and 2: comparison with type-specific rabbit antisera and restriction endonuclease analysis of viral DNA. J Clin Microbiol (1983) 2.50
Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis (1989) 2.41
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med (1983) 2.33
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med (1992) 2.25
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med (1985) 2.23
Infections with herpes simplex viruses (2). N Engl J Med (1986) 2.22
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA (1984) 2.20
Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol (2001) 2.20
Are there sensitive subgroups for the effects of airborne particles? Environ Health Perspect (2000) 2.18
Retracted HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest (2000) 2.17
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. J Virol (1997) 2.16
Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med (1991) 2.12
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis (1999) 2.07
Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. J Infect Dis (1991) 2.06
Epidemiology of Reye syndrome. Epidemiol Rev (1981) 2.04
Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women. JAMA (1994) 2.03
Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med (1989) 2.03
Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol (1999) 2.02
Monoclonal antibodies for diagnosis of infectious diseases in humans. Science (1983) 2.02
Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med (1993) 2.01
Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science (1992) 2.01
The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. Sex Transm Dis (1990) 2.00
Herpes simplex virus proctitis in homosexual men. Clinical, sigmoidoscopic, and histopathological features. N Engl J Med (1983) 1.97
Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med (1991) 1.97
Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood (2001) 1.92
Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med (1987) 1.91
Therapy of herpes zoster with oral acyclovir. Am J Med (1988) 1.89
Therapy for human immunodeficiency virus infection -- what have we learned? N Engl J Med (1996) 1.88
Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sex Transm Dis (1999) 1.88
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis (1998) 1.88
Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis (2000) 1.87
Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS (1990) 1.85
Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis (1997) 1.84
Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol (1994) 1.83
Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. Clin Infect Dis (2000) 1.81
Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi's sarcoma. J Virol (1997) 1.76
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
Diagnostic criteria for influenza B-associated Reye's syndrome: clinical vs. pathologic criteria. Pediatrics (1977) 1.75